BGCOLOR="#FFFFFF">

New Agreements October 1997 - December 1997#
Biotech Pharma Type/Product Area Amount Terms/Details (Month)
Company** Company
(Country) (Symbol/Country)
Abgenix Inc. Pfizer Inc. Research collaboration $30M Abgenix gets license fee, equity
(subsidiary of (NYSE:PFE) and license agreement (equity; investment, research funds and
Cell Genesys Inc.) on use of Abgenix's % ND) milestones totaling $30M; Pfizer
transgenic XenoMouse responsible for product develop-
technology to make fully ment, manufacturing and market-
human antibodies to 3 ing worldwide; Abgenix gets
of Pfizer's antigen targets royalties (12/97)
(undisclosed)
Affymetrix Inc. Novartis Pharma Affymetrix will supply ND Affymetrix gets undisclosed pay-
AG (Switzerland) Novartis with its Gene- ments based on per-data-point
Chip instrumentation, pricing model; payments will
software and DNA probe reflect number and nature of genes
arrays (certain human analyzed; further details ND
and mouse genes) to (12/97)
monitor gene expression
ArQule Inc. Sankyo Co. Ltd. Broad collaboration to $35M Sankyo gets 3-year subscription to
(Japan) discover and optimize ArQule's programs to discover
drug candidates for new lead compounds and then
various therapeutic areas optimize them; ArQule gets pay-
via ArQule's Mapping ments for delivery of programs,
Array and Directed Array milestones and royalties (11/97)
programs
Arris Bristol-Myers Agreement to develop ND Bristol-Myers gets exclusive rights
Pharmaceutical Squibb Co. protease inhibitors for to any HCV protease inhibitors
Corp. (since merged (NYSE:BMY) hepatitis C virus (HCV), produced in collaboration; Arris
with Sequana via Arris's Delta tech- gets research funding, up-front and
Therapeutics Inc. nology milestone payments and royalties
to form Axys (12/97)
Pharmaceuticals Inc.)
Aurora Merck & Co. Inc. Collaborative research $100M Merck will share in development
Biosciences Corp. (NYSE:MRK) and license agreement cost of UHTSS and gets co-exclu-
on Aurora's fluorescent sive access; Aurora gets $33M in
assay technologies and committed research funding, lic-
its ultra-high-throughput ense fees and delivery payments;
screening system Aurora could get more than $100M
(UHTSS) as well as its if Merck exercises certain options
screen development and for additional systems; Aurora
screening services, which also gets royalties on eventual
Merck will use in drug product sales (12/97)
discovery
Axiom Zaiya Inc. and Joint collaboration to ND Axiom gets research funding for
Biotechnologies Nippon Kayaku identify small-molecule 3 years as well as license fees,
Inc.* Co. Ltd. (both anticancer agents; use of milestones and royalties; Axiom
Japan) Axiom's drug discovery will develop cell-based and bio-
technologies to evaluate chemical assays coupled to its
compound libraries for high-throughput pharmacology
lead agents that induce system (HT-PS) to accelerate func-
apoptosis in certain tional profiling of hits; Nippon
cancers (proprietary gets exclusive license for Asia and
molecular target licens- option to territories outside North
ed by Zaiya) America; Zaiya retains product
rights in North America and will
join with Axiom to find U.S. develop-
ment and marketing partner (11/97)
Biogen Inc. Merck & Co. Inc. Collaborative research, $145M Biogen gets up-front payment of
(NYSE:MRK) development and license $15M plus $130M in milestones;
agreement on drugs for Merck gets worldwide rights for
treating asthma and other certain indications, including
inflammatory diseases; asthma, and Biogen gets worldwide
based on inhibiting VLA4 rights for other indications, includ-
receptor molecules (found ing multiple sclerosis and inflam-
on most types of white matory bowel disease; Biogen will
blood cells); in particular, pay $21M in milestones to Merck
an aerosolized anti-VLA4 for any of Biogen's indications;
small-molecule drug and Merck's Japanese affiliate, Banyu
oral VLA4 inhibitors Pharmaceutical Co. Ltd., will
manage clinical development and
approvals in Japan of a Biogen com-
pound (not yet selected) on which
Biogen will retain Japanese market-
ing rights; final agreement subject
to antitrust considerations (12/97)
Biorex Research Abbott Laboratories Agreement for joint $28M Abbott gets license to bimoclomal
and Development (NYSE:ABT) development of Biorex's (equity; and related compounds; Abbott
Co. (Hungary; bimoclomol product % ND) also gets option on right of 1st
wholly owned sub- (synthetic small mole- refusal on other future Biorex
sidiary of BRX Ltd.; cule that activates compounds; Abbott bought
U.K.) expression of heat shock 26,200 non-voting convertible
proteins) for treating shares at $1,068.75 each in BRX
complications of Ltd.; Abbott will commercialize
diabetes (completed product; Biorex gets 10% royalty
Phase II trials in U.K. (letter of intent 10/97; definitive
and Hungary for treating agreement 12/97)
microalbuminuria and
diabetic neuropathy)
Chiron Corp. Bristol-Myers Licenses to Chiron's ND Bristol-Myers and Arris entered a
Squibb Co. hepatitis C virus (HCV) collaboration to develop HCV
(NYSE:BMY) patent portfolio for pro- protease inhibitors (see separate
and Arris Pharma- tease inhibitor research entry above); Chiron granted the
ceutical Corp. (especially use of HCV partners the 1st nonexclusive
NS3 protease) licenses to its patents (12/97)
Cima Labs Inc. Novartis Consumer Development and ND ND (12/97)
Health Inc. license option agreement
(division of Novartis on use of Cima's Ora-
AG; Switzerland) Solv drug delivery tech-
nology (microencapsu-
lated drug formulated
into fast-dissolving oral
tablet) with Novartis
consumer products
CollaGenex Heska Corp. Collaboration to develop ND ND (11/97)
Pharmaceuticals (NASDAQ:HSKA) certain of CollaGenex's
Inc. chemically modified
tetracyclines (inhibit
matrix metalloprotein-
ases) for use in compan-
ion animal health appli-
cations (osteoarthritis,
cancer)
Cubist Eli Lilly and Co. Cubist acquired rights ND Cubist licensed rights to develop,
Pharmaceuticals (NYSE:LLY) to Lilly's Daptomycin manufacture and market product;
Inc. antibiotic to treat infec- Cubist will conduct clinical trials;
tions caused by drug- terms include up-front license fee,
resistant strains of milestones and royalties (11/97)
Staphylococcus aureus
and Enterococci
Dyax Corp.* Merck & Co. Inc. Collaborative study ND Dyax will develop affinity ligands;
(NYSE:MRK) agreement to discover Merck will fund research and pay
and evaluate affinity milestones and royalties to Dyax
ligands for vaccine (10/97)
purification via Dyax's
phage display technology
Emisphere Novartis Pharma Collaboration on oral $35M Novartis gets exclusive worldwide
Technologies Inc. AG (Switzerland) drug delivery of two (equity; rights to oral versions of drugs;
selected large-molecule % ND) Emisphere gets initial fees, equity
compounds of Novartis investment (made in 4 tranches,
(already on market) with maximum aggregate purchase
price of $16M), research funding
and milestones totaling $35M in
all; Emisphere also gets royalties
(12/97)
FibroGen Inc.* Zeneca Ltd. Licensing agreement on ND FibroGen gets exclusive license to
(NYSE:ZEN; U.K.) Zeneca compounds (not develop and market these com-
identified) as potential pounds outside of Europe and
therapeutics for treating Japan, where Zeneca retains rights;
fibrotic disorders and other terms ND (10/97)
diseases
Genetics Institute Chugai Pharma- Functional genomics ND Chugai gets access to Genetics
Inc. (wholly owned ceutical Co. Ltd. agreement; subscription Institute's library of expressed
subsidiary of (Japan) to Genetics Institute's human secreted proteins, their
American Home DiscoverEase protein corresponding cDNAs and a com-
Products Corp.; development platform panion database; futher details
NYSE:AHP) (library of human ND, but similar terms to other
secreted proteins and subscriptions (Chugai is 6th sub-
related database) scriber) (10/97)
Genzyme Corp. Bayer AG Drug discovery agree- $35M Bayer will pay undisclosed up-front
(Germany) ment; use of Genzyme's fee to access Genzyme's library;
library of more than 1 million Bayer will analyze small-molecule
small molecules to iden- leads with its high-speed robotic
tify new drug candidates screens; when it selects develop-
for undisclosed disease ment candidates, Genzyme gets
targets milestones as compounds proceed
through clinical trials (12/97)
Genzyme Parke-Davis Genomics collaboration; $9M If Parke-Davis exercises option to
Molecular (division of service and license take nonexclusive license on
Oncology Warner-Lambert option agreement on use SAGE technology for use in its
(division of Co.; NYSE:WLA) of Genzyme Molecular's internal genomics research pro-
Genzyme Corp.) SAGE technology grams, it will pay Genzyme Mole-
(serial analysis of gene cular $9M in service and license
expression) in pharmaco- fees (11/97)
genomic profiling
(changes in gene expres-
sion in tissues following
exposure to drug can-
didates)
Geron Corp. Boehringer Collaboration on in ND Geron gets funding and mile-
Mannheim GmbH vitro cancer diagnostics; stones; Boehringer Mannheim is
(Germany) use of Geron's tech- responsible for all preclinical and
nologies for detecting clinical product development;
and measuring telomer- Boehringer Mannheim gets exclu-
ase expression and level sive worldwide marketing rights;
of activity (correlates Geron gets royalties; Geron retains
with presence and copromotion rights in U.S.
severity of many cancers) (12/97)
ICAgen Inc.* Abbott Laboratories Research collaboration $12M 3-year collaboration with
(NYSE:ABT) on small-molecule drugs options for renewal; ICAgen gets
for treating selected $12M up front plus milestones and
central nervous system royalties; Abbott will screen com-
and urological disorders; pounds, optimize lead candidates
use of ICAgen's ion and perform all phases of product
channel molecular tar- development (12/97)
gets and its gene family
chemical libraries to
generate selected ion
channel targets
Idec Kirin Brewery License on Idec's $6.3M Idec gets up-front licensing fee of
Pharmaceuticals Co. Ltd. (Japan) vector technology for $6.3M plus royalties; Kirin is 4th
Corp. high expression of and final licensee for this particular
recombinant proteins in platform technology (12/97)
mammalian cells
ImmuCell Corp. Murray Goulburn Licensing agreement on $0.3M License excludes rights to produce
Co-Operative Co. ImmuCell's milk puri- lactoferrin or immunoglobulins;
Ltd. (Australia) fication technology for ImmuCell gets royalties (11/97)
use in manufacturing of
whey protein isolate
(food additive)
Incyte NV Organon (unit Genomic database ND Multiyear agreement; Organon
Pharmaceuticals of Akzo Nobel; agreement for access to gets nonexclusive access to data-
Inc. the Netherlands) Incyte's LifeSeq gene base in exchange for annual fees;
sequence and expression Incyte could get royalties on prod-
database and LifeSeq ucts that Organon develops
GeneAlbum reagent set (10/97)
Rhone-Poulenc SA Genomic database ND Multiyear agreement; Rhone-Pou-
(NYSE:RP; France) agreement for access to lenc gets nonexclusive access to
Incyte's LifeSeq gene database; Incyte gets annual fees
sequence and expression and could get milestones and
database and PathoSeq royalties on products that result
microbial database (12/97)
Innogenetics NV Solvay SA Research collaboration $49.5M Solvay will buy 8.3% equity stake
(EASDAQ:INNX; (Belgium) to discover genes for (8.3% for $35.5M (2M shares at $17.75
Belgium) human diseases, espe- equity) each); Solvay also will pay $4M
cially heart disease and up front and pay $1.5M-$2M for
central nervous system R&D support annually for 5
disorders, and to use them years; Innogenetics also gets mile-
as drug development targets stones and royalties (11/97)
IntraBiotics Pharmacia & Collaboration on topical $35M Companies will codevelop and
Pharmaceuticals Upjohn Inc. antimicrobial com- (equity; promote product in U.S.; they will
Inc.* (NYSE:PNU; pound IB-367 (synthetic % ND) also share profits; Pharmacia gets
U.K.) peptide based on natural exclusive license in all other terri-
host defense peptide tories; IntraBiotics gets royalties;
protegrin); drug is cur- IntraBiotics gets reimbursed for
rently in Phase I trials half of all development expenses
for oral mucositis and also gets $35M in license fees,
(complication of chemo- milestones and equity; IntraBiotics
and radiation therapy) will manufacture product (10/97)
Karo Bio AB* Bristol-Myers Collaboration on drugs $40M 3-year collaboration; Karo
(Sweden) Squibb Co. for treating metabolic Bio could get $40M if two thera-
(NYSE:BMY) disorders (i.e., obesity, pies developed and approved for
hypercholesterolemia) marketing; companies will jointly
based on thyroid hormone manage research and preclinical
receptor beta (TR beta) development; Bristol-Myers gets world-
agonists (based on Karo wide rights to products; Karo Bio
Bio's 3-D structural data) gets milestones and royalties (10/97)
Karo Bio AB* Merck & Co. Inc. Strategic alliance on $80M Agreement valued at US$80M if
(Sweden) (NYSE:MRK) drugs and diagnostics Merck develops and gets regula-
for diseases and con- tory approval for 2 compounds as
ditions that are affected distinct therapies; companies will
by estrogen receptors jointly manage research and pre-
(especially via Karo Bio's clinical development; Merck gets
structural data on estrogen exclusive worldwide rights to com-
receptors alpha and beta) pounds; Karo Bio gets up-front and
milestone payments and R&D
funding as well as royalties (11/97)
Ligand Eli Lilly and Co. Strategic alliance on $194M Ligand gets $49M in research
Pharmaceuticals (NYSE:LLY) products for treating (equity; funding over 5 years plus possible
Inc. diabetes and additional % ND) extra 3 years of research funding,
metabolic diseases; $37.5M in equity investment (at
based on Ligand's premium to market), $12.5M in
intracellular receptor up-front milestones, $75M in addi-
technology, i.e., retinoid tional milestones over 8 years for
X receptor (RXR) successful development of oral
agonists including oral Targretin and 5 other compounds,
Targretin (currently in and royalties; Ligand gets its
Phase II European trials choice of either rights to one of
for treating Type II Lilly's niche cancer products or
diabetes) an additional $20M equity invest-
ment; Ligand also gets milestones,
royalties and options to certain co-
development rights for a Lilly-
selected RXR compound in combi-
nation with a selective estrogen
receptor modulator (SERM); Lilly
gets rights to oral Targretin, exclu-
sive rights to 2nd-generation oral
diabetes compounds and exclusive
rights to Ligand's metabolic dis-
ease technology; additional rights
to use technology to develop a
compound in combination with an
SERM for treating cancer; closing
subject to completion of Ligand's
buyback of Allergan Ligand Ret-
inoid Therapeutics (ALRT) shares
and restructured rights to ALRT
compounds as well as antitrust
considerations (deal announced
10/97; finalized 11/97)
LeukoSite Inc. Becton Dickinson License on chemokines ND Becton Dickinson and its units get
and Co. (and its and receptors for use as exclusive worldwide license to
units Becton Dickin- research and diagnostic commercialize antibodies to sever-
son Immunocyto- reagents al chemokines and chemokine
metry Systems and receptors (including CCR5, the co-
PharMingen; receptor for HIV) for research use;
NYSE:BDX) companies have option to develop
in vitro diagnostics (10/97)
MediGene AG* Hoechst Marion Collaboration on viral $5.8M 3-year collaboration; MediGene
(Germany) Roussel Inc. (sub- vectors for gene ther- will conduct Phase I and II
sidiary of Hoechst apy, especially Medi- trials in melanoma; companies
AG; Germany) Gene's recombinant have option of extending collabor-
adeno-associated virus ation to include other indications;
(AAV) vector technol- Hoechst Marion will fund research
ogy for ex vivo tumor and make GMP-quality vectors;
vaccination in melanoma collaboration is cosponsored by
the Bavarian Science Foundation;
total value $5.8M (DM10M; con-
verted at ratio of DM1.73/US$1)
(11/97)
MedImmune Inc. SmithKline Strategic alliance to $85M MedImmune gets up-front payment,
Beecham plc develop human research funding and milestones
(NYSE:SBH; U.K.) papillomavirus (HPV) totaling $85M; SmithKline gets
vaccines for preventing exclusive worldwide rights to vac-
cervical cancer and cine technology; companies will
genital warts; vaccines collaborate on R&D; MedIm-
based on MedImmune's mune will conduct Phase I and II
virus-like particle tech- trials and manufacture clinical
nology for making non- material; SmithKline will then
infectious form of virus; take over final product develop-
1st candidate MEDI-501 ment, manufacturing, regulatory
(HPV-11) currently in submissions and marketing; Med-
Phase I trials Immune gets royalties; agreement
subject to clearance under anti-
trust law (12/97)
Millennium Monsanto Co. Broad collaboration $218M 5-year agreement; Monsanto
Pharmaceuticals (NYSE:MTC) in genomics; use of will form wholly owned subsidiary
Inc. Millennium's technol- in Cambridge, Mass., as part of
ogies to discover and deal; Millennium will nonexclu-
develop genomics-based sively license and transfer to Mon-
plant and agricultural santo genomics technologies for
products use in R&D of life sciences prod-
ucts (including pharmaceuticals);
Millennium gets $118M in up-front
licensing and technology transfer
fees ($38M in 1997 and $20M
annually for 4 more years); Millen-
nium also gets $100M over 5
years for milestones; Monsanto
will fund R&D at its new subsid-
iary; Millennium gets royalties on
certain plant and animal products;
Millennium has rights to use cer-
tain technologies developed by
new company for nonexclusive
use outside plant and agricultural
areas; collaboration subject to
antitrust clearance (10/97)
Molecular DuPont Agricul- Technology access ND DuPont will use microarray system
Dynamics Inc. tural Products agreement; to further to study gene expression levels in
and Amersham (division of E.I. develop high-throughput agricultural seed and plant species
International plc DuPont de Ne- DNA microarray tech- and to accelerate development of
(U.K.) mours and Co.; nologies products with greater plant health
NYSE:DD) and disease resistance; DuPont will
provide funding and collaborative
expertise in exchange for early
access to latest microarray tech-
nologies (10/97)
Molecular Monsanto Co. Monsanto (including ND ND (12/97)
Simulations Inc.* (NYSE:MTC) its G.D. Searle & Co.
unit) has become member
of Molecular Simulations'
Combinatorial Chemistry
Consortium
Myriad Genetics Bayer Corp. Research collaboration $54M Bayer is 1st pharmaceutical
Inc. (subsidiary to discover gene targets company to license ProNet
of Bayer AG; and develop drugs for database; Myriad gets $54M in
Germany) treating dementia and research and milestone payments;
depression via Myriad's Myriad will use its database of
positional cloning and Utah families to identify genes of
ProNet technology interest; 5-year collaboration;
(protein interaction net- Bayer gets worldwide therapeutic
work; database of human rights for discoveries in dementia
proteins and their bio- and depression; Myriad retains
chemical pathways) rights to diagnostics in those areas
and all rights outside those fields
(11/97)
NanoSystems Rhone-Poulenc Feasibility study to ND Rhone-Poulenc Rorer has exclu-
LLC* Rorer Inc. evaluate new formula- sive option to license technology;
(subsidiary of tions of RPR's asthma further details ND (12/97)
Rhone-Poulenc SA; drug triamcinolone
NYSE:RP; France) acetonide (respiratory
steroid), made via
NanoCrystal technology
(for delivery of poorly
water-soluble drugs)
NaviCyte Inc.* SmithKline Collaboration on use ND SmithKline will provide data and
Beecham plc of NaviCyte's compu- make initial and milestone pay-
(NYSE:SBH; U.K.) tational biology tools to ments; SmithKline gets license to
identify new candidates software and computational
for drug development models for use with its compound
(IDEA simulation soft- libraries (11/97)
ware enables prediction
of drug's pharmaco-
kinetic outcome in
humans)
Neose McNeil Specialty Joint program to devel- ND ND (11/97)
Technologies Inc. Products Co. op commercially prac-
(subsidiary of tical, large-scale enzy-
Johnson & John- matic manufacturing
son; NYSE:JNJ) process for certain
naturally occurring
oligosaccharides for
human health care
applications
NetGenics Inc.* Abbott Laboratories Use of NetGenics' ND Renewable 3-year agreement;
(NYSE:ABT) Synergy software and NetGenics will tailor Synergy for
services to manage data use with Abbott's data; financial
generated by Abbott's terms ND (12/97)
genomics research
program
Nova Molecular Amersham Option agreement on ND Amersham Pharmacia will make
Inc.* (Canada) Pharmacia Biotech sequencing project to (includes undisclosed equity investment in
Ltd. (Sweden) identify unique gene equity) Nova Molecular; Amersham
variants in 4 specific Pharmacia gets right to research
central nervous system- market applications of DNA
related genes (pharma- analysis-related discoveries from
cogenomics study to this project (10/97)
identify responders and
non-responders to
certain drugs)
Pharmacopeia Bristol-Myers Research collaboration $40M 3-year agreement; Bristol-
Inc. Squibb Co. to identify and optimize Myers gets combinatorial librar-
(NYSE:BMY) small-molecule drug ies of chemical structures for
candidates for two testing in its own internal research
chemokine receptors programs; Pharmacopeia gets up-
related to inflammatory front payment, annual research
and immunological funding and milestones for total
diseases; use of Pharma- of $40M; Pharmacopeia could get
copeia's ECLiPS and additional milestones from results
high-throughput screen- of Bristol-Myers' screening of its
ing technologies libraries; Pharmacopeia gets
royalties (12/97)
Pharmacyclics Alcon Pharma- Assignment of rights to ND Alcon gets worldwide rights to
Inc. ceuticals Ltd. Lu-Tex photosensitizer compound for ophthalmic indica-
(affiliate of Alcon (lutetium texaphyrin, a tions; Alcon will conduct and fund
Laboratories Inc., synthetic molecule that all costs for development and
a subsidiary of captures and focuses product registration worldwide;
Nestle SA; France) light energy) for oph- Pharmacyclics gets up-front pay-
thalmic indications, ment and milestones as well as
including age-related royalties (12/97)
macular degeneration
Pharmacyclics Nycomed ASA Licensing agreement on $28M Nycomed gets exclusive rights to
Inc. (NYSE:NYD; Lu-Tex photosensitizer develop and market product in
Norway; in process (lutetium texaphyrin, a Europe, Asia, and Central and
of merging with synthetic molecule that South America; Pharmacyclics
Amersham Inter- captures and focuses gets $14M in license fees, mile-
national plc to light energy) for photo- stones and development costs for
form Nycomed- dynamic treatment of initial indication and $14M for subse-
Amersham plc) cancer (currently in quent cancer indication; Pharmacyclics
Phase II trials for breast gets royalties and retains rights in
cancer) U.S., Canada and Japan; companies
will share costs for product develop-
ment and approval in U.S., but each
will make regulatory submissions in
own territories; Pharmacyclics will
supply bulk drug substance; Nycomed
will make finished product (10/97)
Qiagen NV Organon Teknika Licensing agreement on ND Qiagen gets worldwide nonexclu-
(the Netherlands) BV (unit of Akzo Organon's "boom" sive license to develop, manufac-
Nobel NV; the patents (nucleic acid ture and market products using
Netherlands) purification technology) technology in all markets and for
all applications, with no field-of-
use limitations (11/97)
Ribozyme Parke-Davis Letter of intent on ND Ribozyme Pharmaceuticals will
Pharmaceuticals (division of collaboration to evaluate design and synthesize ribozymes
Inc. Warner-Lambert specific disease-related against target genes designated by
Co.; NYSE:WLA) genes for drug inter- Parke-Davis; collaboration subject
vention using Ribo- to negotiation of definitive agree-
zyme's target validation ment; financial terms ND (12/97)
technology (involves
use of ribozymes to dis-
cover gene function and
validate gene targets)
Scios Inc. The DuPont Merck Research collaboration $3M DuPont Merck will fund research
Pharmaceutical Co. on drugs that prevent (equity; and be responsible for developing
or retard disease pro- % ND) and commercializing products;
gression in Alzheimer's; DuPont Merck will make $3M
initial focus on use of equity investment in Scios and pay
Scios' high-throughput milestones and royalties on sales
screens on DuPont Merck (11/97)
compounds to identify leads
Scriptgen Hoechst Marion Collaboration to iden- $9M Scriptgen gets $6M in technology
Pharmaceuticals Roussel Inc. (sub- tify fungal targets and (equity; access fees (through 1/98) plus
Inc. (IPO pending) sidiary of Hoechst develop antifungal drugs % ND) $3M equity investment concurrent
AG; Germany) via Scriptgen's high- with Scriptgen's IPO; Scriptgen
throughput target also gets R&D funding, mile-
identification and stones and royalties; Hoechst
validation systems as Marion will actively participate in
well as affinity screens research; Hoechst Marion will be
responsible for global product
development and marketing (10/97)
Sepracor Inc. Schering-Plough License agreement on $5M Schering-Plough gets exclusive
Corp. (NYSE:SGP) Sepracor's patent on worldwide rights to DCL; Sepra-
DCL (descarboethocy- cor gets up-front license fee of $5M
loratadine, a metabolite and royalties that escalate over
of the active agent in time (12/97)
Claritin nonsedating
antihistamine)
Sequana Parke-Davis Broad-based genomics $103M Sequana gets $103M in combina-
Therapeutics Inc. (division of alliance to develop tion of up-front licensing fees,
(since merged Warner-Lambert therapeutics for treat- research funding and milestones;
with Arris Pharma- Co.; NYSE:WLA) ing schizophrenia and Sequana also gets royalties on
ceutical Corp. to bipolar disorder via sales of any small-molecule thera-
form Axys Pharma- Sequana's capabilities in peutics; 5-year alliance is extend-
ceuticals Inc.) gene discovery, function- able in 1-year increments to 8
al genomics, bioinformatics years, with concomitant increases
and high-throughput in research funding; Parke-Davis
screening gets exclusive worldwide rights to
any small-molecule therapeutics;
Sequana retains worldwide rights
to recombinant protein, antisense,
gene therapy, vaccine, diagnostic,
prognostic and pharmacogenetic
products and services; Parke-
Davis gets nonexclusive license
to use certain of Sequana's bio-
informatics software tools (11/97)
Signal Ares-Serono Collaboration to identify $59M Signal gets $8M equity investment
Pharmaceuticals Group small-molecule modu- (equity; and $9M over 3 years to fund
Inc.* (Switzerland) lators in the NF-kB gene % ND) research plus about $42M in mile-
regulation pathway stones (at least $10M for each
(includes broad set of product resulting from research);
genes for inflammatory Signal also gets royalties; Ares-
molecules); key targets Serono gets worldwide rights to all
are proteins IKK-1, IKK-2 products; Signal retains option to
and a 3rd regulatory copromote in U.S.; Signal respon-
protein as well as NF-kB sible for target identification and
inducing kinase validation, high-throughput screen-
ing and lead optimization; Ares-
Serono will conduct all further
product development, approvals
and marketing for all indications
except in Asia (12/97)
T Cell Sciences Novartis Pharma Option agreement on $25M T Cell gets $5M in annual option
Inc. AG (Switzerland) TP10 (soluble comple- (equity; fees and cost of clinical supplies
ment receptor 1; inhibits % ND) of TP10 in return for granting
complement activation) Novartis a 2-year option to license
for use in xeno- and allo- worldwide exclusive rights (except
transplantation Japan) to TP10 in fields of xeno-
and allotransplantation; if Novar-
tis exercises option, T Cell gets
$20M in equity investment, licens-
ing fees and milestones; T Cell
could also get additional research
funding and royalties; T Cell
retains rights to all other indica-
tions except those already assign-
ed to other partners in Japan
(10/97)
TheraTech Inc. The Procter and Agreement to develop $35M Companies will work together on
Gamble Co. transdermal testosterone clinical development of products;
(NYSE:PG) and combination estra- Procter and Gamble will fund all
diol/testosterone hormone development; TheraTech gets R&D
replacement patches for payments and milestones of
women (testosterone $35M as well as royalties; Thera-
patch currently in Phase Tech will manufacture products
II trials for treating and retains certain copromotion
diminished libido in rights; Procter and Gamble gets
surgically menopausal worldwide rights (except Asia)
women) (12/97)
Titan Novartis Pharma Agreement on Titan's $38M Titan gets up-front payment of
Pharmaceuticals AG (Switzerland) antipsychotic small- (equity; $18M in license fees and reimburse-
Inc. molecule drug Iloper- % ND) ment of R&D costs plus a $5M
idone (blocks serotonin equity investment; Titan will get
and dopamine); in clin- $5M milestone when it submits an
ical development for NDA in U.S. or Europe and $10M
treating schizophrenia on product approval; Novartis will
and related disorders fund Phase III trials and product
registration costs worldwide
(except Japan); Titan gets royalties
on sales (11/97)
Vanguard Medica Abbott Laboratories Licensing agreement on $3M Abbott has option to develop and
Group plc (U.K.) (NYSE:ABT) VML 530 (oral dose, (equity; commercialize product after Van-
inhibitor of 5-lipoxygen- % ND) guard completes Phase II trials
ase activating protein) (now in preclinical stage); if it
for treating asthma exercises option, Abbott will buy
US$3M in new common stock of
Vanguard (at market price) and
Vanguard gets royalties on sales
(10/97)
Vanguard Medica Sankyo Co. Ltd. Licensing agreement on ND Sankyo gets exclusive rights to
Group plc (U.K.) (Japan) VML 252 (oral dose, develop and market product in
calcium-free phosphate Japan and Far East; Sankyo will
binding agent) for treat- make series of payments for rights
ing hyperphosphatemia and will cover part of development
(elevated blood phosphate) costs; Vanguard will continue clin-
(currently in U.S. Phase ical development in U.S. and
II trial in patients with Europe; Vanguard will provide
chronic kidney failure) bulk compound to Sankyo for its
own trials; Vanguard gets royalties
on Sankyo's sales (10/97)
Verigen Inc.* Italchimici SpA Licensing agreement ND Italchimici will develop and mar-
(Italy) on Verigen's PASSTNF- ket product in Italy; Verigen gets
alpha product (porcine- up-front license fee and royalties;
derived polyclonal anti- Verigen retains manufacturing
body to tumor necrosis rights (10/97)
factor-alpha) for use in
treating rheumatoid
arthritis and Crohn's
disease
Vical Inc. Rhone-Poulenc License on use of $1M Rhone-Poulenc Rorer gets exclu-
Rorer Inc. Vical's "naked" DNA sive worldwide license to technol-
(subsidiary of gene delivery technol- ogy (which will be used by its
Rhone-Poulenc SA; ogy to develop certain RPR Gencell division); Vical gets
NYSE:RP; France) gene therapy products initial fee of $1M plus milestones
for treating neuro- and royalties (10/97)
degenerative diseases
Vion Boehringer Licensing agreement $50M Boehringer Ingelheim gets exclu-
Pharmaceuticals Ingelheim GmbH on Vion's Promycin (equity; sive rights to product outside
Inc. (Germany) anticancer agent (a % ND) North America; Vion gets exclu-
bioreductive alkylating sive copromotion rights in North
agent; currently in America; Vion gets up-front
Phase III trials as adjunct license fee, milestones and royal-
to radiation therapy for ties; companies will share develop-
treating head and neck ment costs worldwide; Boehringer
cancer) Ingelheim will buy $3M equity in
Vion (at premium to market); Vion
will manufacture and supply prod-
uct for all territories (11/97)
Virus Research SmithKline Collaboration on Virus ND Virus Research gets license fees,
Institute Inc. Beecham plc Research's live oral milestones and royalties; Smith-
(NYSE:SBH; U.K.) rotavirus vaccine (virus Kline gets exclusive worldwide
causes acute diarrhea rights; Virus Research will contin-
and dehydration in ue to conduct U.S. Phase II clinical
infants) trials, after which SmithKline has
right to assume responsibility for
all subsequent development;
SmithKline Biologicals will manu-
facture product (12/97)
Xenova Discovery EG&G Wallac Formation of joint ND Partners will each license certain
Ltd. (subsidiary of (Finland) venture, to be called proprietary technologies to the
Xenova Group plc; Advant; to provide joint venture; partners will share
U.K.) customized products profits (12/97)
and services (e.g., high-
throughput screens) for
identification of new
drug leads
NOTES:
# This chart contains information on new agreements only, covering the time between 10/1/97 and 12/31/97. It does not include arrangements that are classified strictly as production, manufacturing, marketing and/or distribution and supply agreements; a chart covering these arrangements will appear in the 1/26/98 issue of BioWorld Financial Watch.
A chart covering modified agreements and terminated agreements between big pharma and biotech companies for the same time period (10/1/97 - 12/31/97) will also appear in the 1/26/98 issue of BioWorld Financial Watch.
ND = Not disclosed, reported and/or available
* Private companies are indicated with an asterisk.
** Unless otherwise noted, the trading symbols for public biotechnology companies can be found by referring to the BioWorld Stock Report For Public Biotechnology Companies on pp. 17-18.

No Comments